Dominique Malka
多米尼克·马尔卡
MD, PhD
Senior Medical Oncologist; Head, Gastrointestinal Oncology Unit高级肿瘤内科医生；消化系统肿瘤科主任
👥Biography 个人简介
Dominique Malka, MD, PhD is a senior oncologist at Gustave Roussy who was a pivotal participant in the PRODIGE 4/ACCORD 11 trial—one of the most influential studies in the history of pancreatic cancer treatment—that established FOLFIRINOX as a superior first-line regimen over gemcitabine alone in metastatic PDAC. He leads ongoing investigations into FOLFIRINOX modifications, maintenance strategies, and the integration of novel agents with backbone chemotherapy in pancreatic and biliary cancers. His work at one of Europe's largest oncology centers has shaped treatment guidelines across multiple continents.
🧪Research Fields 研究领域
🎓Key Contributions 主要贡献
FOLFIRINOX Standard of Care Establishment
Co-investigator on PRODIGE 4/ACCORD 11 phase III trial demonstrating that FOLFIRINOX significantly prolonged median overall survival compared to gemcitabine alone in metastatic PDAC, transforming international first-line treatment guidelines.
Maintenance Therapy in Advanced PDAC
Led and participated in trials evaluating olaparib and other maintenance strategies following induction FOLFIRINOX, contributing to paradigm shifts in the sequential management of pancreatic cancer.
Biliary Tract Cancer Systemic Therapy
Contributed to gemcitabine/cisplatin studies and immunotherapy combination trials in biliary tract cancers, helping define contemporary first-line and second-line standards for CCA and gallbladder cancer.
Representative Works 代表性著作
FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer
New England Journal of Medicine (2011)
Landmark PRODIGE 4/ACCORD 11 trial demonstrating superior survival with FOLFIRINOX vs. gemcitabine in metastatic PDAC, establishing a new standard of care.
Randomized Phase II Study of Gemcitabine plus Cisplatin Compared with Gemcitabine Alone in Advanced Biliary Tract Cancer
Journal of Clinical Oncology (2012)
Contributed to the evidence base supporting gemcitabine/cisplatin as a first-line regimen in advanced biliary tract malignancies.
🏆Awards & Recognition 奖项与荣誉
📄Data Sources 数据来源
Last updated: 2026-01-15 | All information from publicly available academic sources
Related Experts 相关专家
Hope S. Rugo
University of California, San Francisco (UCSF)
Maryam B. Lustberg
Yale School of Medicine / Yale Cancer Center
Sara M. Tolaney
Dana-Farber Cancer Institute / Harvard Medical School
Carlos H. Barrios
PUCRS (Pontifical Catholic University of Rio Grande do Sul) / Hospital São Lucas, Porto Alegre, Brazil
关注 多米尼克·马尔卡 的研究动态
Follow Dominique Malka's research updates
留下邮箱，当我们发布与 Dominique Malka（Gustave Roussy Cancer Campus）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment